Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash from Operations (2016 - 2025)

Historic Cash from Operations for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $30.9 million.

  • CorMedix's Cash from Operations rose 32605.65% to $30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.0 million, marking a year-over-year increase of 23534.01%. This contributed to the annual value of -$50.6 million for FY2024, which is 3177.65% down from last year.
  • According to the latest figures from Q3 2025, CorMedix's Cash from Operations is $30.9 million, which was up 32605.65% from $30.0 million recorded in Q2 2025.
  • CorMedix's 5-year Cash from Operations high stood at $30.9 million for Q3 2025, and its period low was -$17.3 million during Q1 2024.
  • Moreover, its 5-year median value for Cash from Operations was -$5.9 million (2021), whereas its average is -$1.6 million.
  • As far as peak fluctuations go, CorMedix's Cash from Operations plummeted by 30981.46% in 2021, and later skyrocketed by 32605.65% in 2025.
  • Over the past 5 years, CorMedix's Cash from Operations (Quarter) stood at -$5.9 million in 2021, then fell by 4.86% to -$6.2 million in 2022, then crashed by 68.87% to -$10.4 million in 2023, then skyrocketed by 45.98% to -$5.6 million in 2024, then skyrocketed by 649.58% to $30.9 million in 2025.
  • Its Cash from Operations was $30.9 million in Q3 2025, compared to $30.0 million in Q2 2025 and $19.7 million in Q1 2025.